PI4K2A — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL580610	0.58	10/20
SCHEMBL8273	0.54	10/20
SCHEMBL9120	0.54	10/20
SCHEMBL258584	0.54	10/20
SCHEMBL106573	0.59	9/20
SCHEMBL42335	0.57	8/20
SCHEMBL42314	0.56	8/20
SCHEMBL8566	0.53	8/20
SCHEMBL24640	0.50	8/20
SCHEMBL385843	0.50	7/20
SCHEMBL134910	0.54	6/20
SCHEMBL397509	0.50	6/20
SCHEMBL48258	0.41	6/20
SCHEMBL179434	1.00	5/20
SCHEMBL179409	0.71	5/20
SCHEMBL179437	0.71	5/20
SCHEMBL179458	0.71	5/20
SCHEMBL179551	0.54	5/20
SCHEMBL397656	0.45	5/20
SCHEMBL8565	0.37	5/20

Clinical trials — most relevant to PI4K2A by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Effect of the Preoperative Oral Carbohydrate Attenuating Immediate Postoperative Insulin Resistance on PI3K Dependent Signaling Pathway	PHASE4	COMPLETED
Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
A Phase II Single-arm Intervention Trial of Nelfinavir in Patients With Grade 2/3 or 3 Cervical Intraepithelial Neoplasia	PHASE2	WITHDRAWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Analysis of Tissues From Patients in Trial of Myo-Inositol to Prevent Lung Cancer	PHASE1	COMPLETED
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101	PHASE1	WITHDRAWN
BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)	PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Combining Gene Variants to Improve Risk Prediction for Metabolic (Dysfunction)- Associated Fatty Liver Disease and Its Progression to Cirrhosis in Indian Individuals With Type 2 Diabetes	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
PIK3CA in HER2+ BC and pCR Trial	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Study of Proteus Syndrome and Related Congenital Disorders	nan	RECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN
Free Fatty Acid Induced Insulin Resistance	nan	COMPLETED
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
PI3K Pathway Activation Markers in ER-Positive, HER2-Negative Breast Cancer: A Clinicopathologic Study	nan	NOT_YET_RECRUITING
Identification of Novel Targetable Kinases in SR-a GvHD	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PI4K2A binder may also engage these)

Protein	Name	Similarity
Q99M64	—	1.000	Q99M64 →
Q2TBE6	—	1.000	Q2TBE6 →
Q6PE18	—	1.000	Q6PE18 →
Q505I0	—	1.000	Q505I0 →
Q08B31	—	1.000	Q08B31 →
Q6DCQ8	—	1.000	Q6DCQ8 →
Q5XIL2	—	0.998	Q5XIL2 →
Q5ZIK0	—	0.998	Q5ZIK0 →
Q49GP5	—	0.998	Q49GP5 →
PI4K2B	Phosphatidylinositol 4-kinase type 2-beta	0.997	landscape →
Q8CBQ5	—	0.997	Q8CBQ5 →
A4VCL2	—	0.992	A4VCL2 →
Q28G26	—	0.992	Q28G26 →
Q9VLA1	—	0.989	Q9VLA1 →
B2B1M4	—	0.989	B2B1M4 →
Q7TNB8	—	0.989	Q7TNB8 →
Q0KHV6	—	0.989	Q0KHV6 →
Q7PZD5	—	0.989	Q7PZD5 →
Q8W3F9	—	0.988	Q8W3F9 →
A8E7C5	—	0.988	A8E7C5 →
Q9D5Z5	—	0.988	Q9D5Z5 →
A1ZAB5	—	0.988	A1ZAB5 →
F4IF36	—	0.988	F4IF36 →
Q525S7	—	0.987	Q525S7 →
Q803H0	—	0.987	Q803H0 →
P43125	—	0.987	P43125 →
A6S544	—	0.987	A6S544 →
Q92562	—	0.987	Q92562 →
D3ZKV9	—	0.987	D3ZKV9 →
A8WRG3	—	0.987	A8WRG3 →